Subscribe to Newsletter

Retina

Business & Profession Retina

20/200 Drivers

| Mark Hillen

Americans love their cars and in many places you’re virtually stranded if you don’t drive. So does vision loss stop elderly Americans from driving?

Subspecialties Professional Development

Not All Big Pharma Loves Ophtho

| Mark Hillen

While other pharmaceutical companies are buying into ophthalmology, Pfizer is heading for the hills

Subspecialties Retina

Achieving Consensus on the Treatment of DME with ILUVIEN®

Who should receive ILUVIEN® for the treatment of chronic DME-associated vision impairment

Subspecialties Retina

Treating Macular Edema Following RVO

| Marianne Shahsuvaryan

The last decade has seen some great advances, but there's still room for improvement…

Subspecialties Retina

Predicting Anti-VEGF Treatment Outcomes

| Sebastian Waldstein

Predicting treatment outcomes manages their expectations and improves your care.

Subspecialties Retina

Loss of Traction

| Mark Hillen

If you had VMT or MH and could avoid vitrectomy, you would. Might ocriplasmin let you?

Subspecialties Retina

Gazing into the MYRROR

| Mark Hillen

Bayer and Regeneron have presented the phase III trial data for aflibercept treatment of myopic choroidal neovascularization

Subspecialties Cornea / Ocular Surface

A Shock to the System

| Florian Gekeler

Can transcorneal electrical stimulation help reverse retinal degeneration in retinitis pigmentosa? Ongoing clinical trials suggest that it may.

Subspecialties Retina

Snappy Snaps

| Scott Mackie

Screening macular pigment density aids early detection of age-related macular degeneration. Here’s a guide to a snappy one-minute test using autofluorescence spectrometry.

Business & Profession Retina

Genuine Telescopic Vision

| David Keegan

Why I offer implantable miniature telescopes (IMTs) to my patients with bilateral end-stage macular degeneration.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer element

This new disclaimer element is now part of all brands. It is editable on the start page and will be shown on all pages

Once confirmed we store a cookie to not show the disclaimer again.